Non-small cell lung cancer (NSCLC), the most commonly fatal malignancy in the United States, accounts for approximately 85 percent of all lung cancer. Most patients are... | [more]
Welcome to Dana-Farber/Harvard Cancer Center
Dana-Farber/Harvard Cancer Center (DF/HCC) is the largest comprehensive cancer center in the world, bringing together the cancer research efforts of our seven member institutions: Beth Israel Deaconess Medical Center, Brigham and Women’s Hospital, Children’s Hospital Boston, Dana-Farber Cancer Institute, Harvard Medical School, Harvard School of Public Health, and Massachusetts General Hospital.Funded by a grant from the National Cancer Institute, we have joined these seven renowned Harvard-affiliated medical centers into one collective force dedicated to the fight against cancer. Based in Boston, DF/HCC consists of more than 1,000 researchers with a singular goal — to find new and innovative ways to combat cancer.
Announcements
- Community Health Educator Administrative Supplement Opportunity Posted: 07-14-10
- Train the Trainer in Cultural Competency in Healthcare Posted: 07-02-10
- DF/HCC 2010 Member Survey Raffle Winners Posted: 06-21-10
Latest Cancer News
Trials target abnormal fusion gene in lung cancer
Ovarian cancer research takes center stage
Most women with ovarian cancer are diagnosed in their 60s and 70s with advanced stage disease that has spread throughout the abdomen. Although the cancer usually responds to... | [more]
New Core: Recombinant Protein Expression and Purification
The Recombinant Protein Expression and Purification (RPrEP) Core was launched in 2009 to provide a cost-effective resource to the DF/HCC community for expression and... | [more]
Tissue Microarray and Imaging Core
The Tissue Microarray and Imaging Core is dedicated to the construction and evaluation of high quality tissue microarrays for cancer research. Core services include... | [more]
